ArticleAntimicrobial agents and chemotherapy2021
Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Dihydrotanshinone I as a novel signal transducer and activator of transcription 3 inhibitor for glioblastoma treatment.Journal of translational medicine · 2026Article
- 2-oxoglutarate:acceptor oxidoreductase-catalyzed redox cycling effectively targets coccoid forms of Helicobacter pylori.Nature communications · 2025Article
- Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins AgainstMicroorganisms · 2025Article
- Antagonist Targeting the Species-Specific Fatty Acid Dehydrogenase/Isomerase FabX for Anti-H. pylori Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025Review
- Nanomaterials: A Prospective Strategy for Biofilm-FormingInternational journal of nanomedicine · 2025Review
- Opportunities forMicroorganisms · 2024Review
- Loureirin A is a narrow-spectrum antimicrobial agent againstAntimicrobial agents and chemotherapy · 2024Article
- Polymorphism of virulence genes and biofilm associated with in vitro induced resistance to clarithromycin in Helicobacter pylori.Gut pathogens · 2023Article
- Biofilm ofAntibiotics (Basel, Switzerland) · 2023Review
- Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies forTropical medicine and infectious disease · 2023Review
- Spatiotemporal and Transcriptional Characterization on Tanshinone Initial Synthesis inInternational journal of molecular sciences · 2022Article
- Review
- Rehabilitation of Sepsis Patients with Acute Kidney Injury Based on Intelligent Medical Big Data.Journal of healthcare engineering · 2022Article
- Diagnostic Value of SonoVue Contrast-Enhanced Ultrasonography in Nipple Discharge Based on Artificial Intelligence.Journal of healthcare engineering · 2021Article
- Evaluation of the Effect of PDCA in Hospital Health Management.Journal of healthcare engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.